Neye Fonden - Targeting deregulation of lipid metabolism in advanced renal cell carcinoma: a promising therapeutic strategy

Renal cell carcinoma of the clear cell type (ccRCC) is the most common form of kidney cancer and among the ten most common cancers, worldwide. Over the past decade, marked progresses in the treatment of ccRCC have been made with targeted agents such as Sunitinib, however, clinical data have shown that most of the patients with primary or metastatic ccRCC acquire resistance to this medication within a relative short time.
ccRCC is characterized by specific genetic alterations which result in heightened angiogenesis, intra-tumoral heterogeneity and aberrant lipid metabolism.
In recent years, the elevated immune infiltration characteristic of ccRCC has gained increase interest in view of possible new therapeutic strategies. However, emerging evidence shows that deregulated lipid metabolism may substantially interfere with the anti-cancer immune response.

Renal celle karcinom (RCC) er den mest almindelige form for nyrekræft, og den er karakteriseret ved usædvanlig høj resistens overfor stråle- og kemoterapi, hvilket skyldes mutationer i gener, der styrer celleproliferation.
En af de mest succesfulde behandlingsstrategier mod RCC er baseret på Sunitinib der er et stof som hæmmer cellevækst og forhindrer dannelse af nye blodkar. Selvom Sunitinib hæmmer kræftcellernes vækst ved terapeutisk dosis, udvikler de fleste patienter resistens efter få måneders behandling.
Resistensen mod Sunitinib skyldes en lang række effektor-molekyler, og denne udfordring skal løses ved hjælp af nye strategier og medikamenter.
En af de lovende terapeutiske strategier er baseret på behandling med immunterapeutiske stoffer, da RCC udviser høj infiltration af T-celler.